Want to join the conversation?
Excluding 3Q14 clinical trials revenue, $DGX's consolidated revenue was $1.88Bil, up by 0.9% vs. 3Q14 on an equivalent revenue basis. GAAP reported revenues were lower by 1.3%, while diagnostic information services revenue was flat to prior year. Revenue per acquisition was 0.2% better than 3Q14.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.